Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Eligibility Criteria

• * Age ≥ 18 years
• * History of cancer-related fatigue as defined by an average score ≥ 4 over the past 30 days on the numeric analogue scale. Patients can answer questions orally rather than completing worksheet
• * Baseline control of insomnia: Insomnia ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
• * Baseline control of pain: Pain ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
• * Life expectancy ≥ 6 months
• * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
• * Hemoglobin ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion) (≤ 180 days prior to registration)
• * Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal (ULN) (≤ 180 days prior to registration)
• * Creatinine ≤ 1.5 x ULN (≤ 180 days prior to registration)
• * No clinical suspicion of hypothyroidism within 180 days prior to registration \[if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone (TSH) \< 5 milli-international units per liter (mIU/L) is required\]
• * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
• * Ability to complete questionnaire(s) by themselves or with assistance
• * Provide informed consent
• * Any known hypersensitivity to ginseng
• * Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for ≥ 30 days and plan to continue such for 8 weeks. Exercise is allowed
• * Psychiatric disorder such as poorly controlled depression, manic depressive disorder, obsessive compulsive disorder, or schizophrenia (defined per medical history)
• * Use of erythropoietic agents ≤ 6 months
• * Uncontrolled hypertension on more than three occasions (diastolic blood pressure ≥ 100, systolic ≥ 160) measured ≤ 180 days prior to randomization
• * Surgery that required general anesthetic ≤ 30 days prior to randomization
• * Malnutrition, active infection, severe depression, or significant pulmonary disease and cardiovascular disease (as determined by the attending clinician), as they could impact fatigue
• * Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, guarana, or anything called an "adaptogen")
• * Currently using an antidiabetic drug, warfarin or monamine oxide inhibitor
• * Treating provider anticipates a change to the anti-cancer treatment program in the next 8 weeks (i.e., the intervention period)